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Inhibition of autophagy sensitizes malignant pleural
mesothelioma cells to dual PI3K/mTOR inhibitors
N Echeverry1, G Ziltener1, D Barbone2, W Weder3, RA Stahel1, VC Broaddus2 and E Felley-Bosco*,1
Malignant pleural mesothelioma (MPM) originates in most of the cases from chronic inflammation of the mesothelium due to
exposure to asbestos fibers. Given the limited effect of chemotherapy, a big effort is being made to find new treatment options. The
PI3K/mTOR pathway was reported to be upregulated in MPM. We tested the cell growth inhibition properties of two dual PI3K/
mTOR inhibitors NVP-BEZ235 and GDC-0980 on 19 MPM cell lines. We could identify resistant and sensitive lines; however, there
was no correlation to the downregulation of PI3K/mTOR activity markers. As a result of mTOR inhibition, both drugs efficiently
induced long-term autophagy but not cell death. Autophagy blockade by chloroquine in combination with the dual PI3K/mTOR
inhibitors significantly induced caspase-independent cell death involving RIP1 in the sensitive cell line SPC212. Cell death in the
resistant cell line Mero-82 was less pronounced, and it was not induced via RIP1-dependent mechanism, suggesting the
involvement of RIP1 downstream effectors. Cell death induction was confirmed in 3D systems. Based on these results, we identify
autophagy as one of the main mechanisms of cell death resistance against dual PI3K/mTOR inhibitors in MPM. As PI3K/mTOR
inhibitors are under investigation in clinical trials, these results may help interpreting their outcome and suggest ways for
intervention.
Cell Death and Disease (2015) 6, e1757; doi:10.1038/cddis.2015.124; published online 7 May 2015
Malignant pleural mesothelioma (MPM) is sensitive to
phosphatidylinositol 3-kinase/mammalian target of rapamycin
(PI3K/mTOR) signaling inhibitors due to the activation of PI3K/
mTOR signaling.1,2 The activation may result from inactivation
of INP4A phosphatase, which is downregulated in 44% of
MPM (presented at IMIG2014), or alterations in PI3K signaling
components, which are mutated in 9% of MPM,3 while
receptor tyrosine kinase mutations/amplifications have not
been identified in two recent high-throughput studies.4,5
One of the tumor-suppressor genes frequently mutated in
MPM is NF2 and NF2-null cells were shown to be sensitive to
growth-inhibitory effects of rapamycin6 via mechanisms
involving PI3K signaling-independent mTORC1 activation.
However, the mTOR inhibitor, everolimus, showed no ther-
apeutic benefit in unselected MPM patients.7 As mTORC1
inhibitors often lead to a feedback activation of PI3K activation
in cancers,8,9 we postulated that dual PI3K–mTOR inhibitors
may yield greater therapeutic benefit. Furthermore, NF2 was
also shown to inhibit PI3K activity by binding to PI3K
enhancer-L (PIKE-L), which disrupts binding of PIKE-L to
PI3K10 and loss of NF2 in schwannoma was shown to
sensitize to PI3K inhibitors.11
In a screen on the dual PI3K/mTOR inhibitor NVP-BEZ235,
within the Sanger Institute/MGH’s ‘Genomics of Drug Sensi-
tivity’ screening panel,12 CDKN2A deletion was shown to be
associated with increased sensitivity. Because NF2 and
CDKN2A are indeed the genes most frequently mutated in
MPM, blocking PI3K/mTOR signaling might be a valid
approach to circumvent the difficulty of applying targeted
therapy in the absence of an identified oncogene. The
rationale for targeting the PI3K/mTOR pathway is also
supported by the association of increased activity with
a worse clinical outcome.13,14
NVP-BEZ235(ref 15) and GDC-0980(ref 16) are small-molecule
inhibitors of class I PI3K and mTOR (mTORC1 and mTORC2).
GDC-0980 has been tested in phase I studieswhere the phase I
extension cohort showed two objective responses among 26
patients with mesothelioma.17 Despite these encouraging
results, this drug will not be explored further because of side
effects observed in another clinical trial.18 This, however, should
not deter us for trying to find means to improve the antitumor
effect of this class of agents. We have previously shown that
PI3K/mTOR signaling inhibition sensitizes mesothelioma cells
to drugs that are effluxed viaABCG2 transporter by inhibiting the
function of ABCG2.19 In this study, we aimed at identifying the
underlying mechanisms responsible for sensitivity versus
resistance towards PI3K/mTOR inhibition in a large panel of
mesothelioma cell lines. We observed that PI3K/mTOR inhibi-
tion increases autophagic rate, which constitutes an efficient
mechanism of resistance by inducing growth arrest and survival.
However, blocking autophagy, which per se affects cell growth,
is synthetically lethal when combinedwith PI3K/mTOR inhibitors
by a mechanism involving receptor-interacting protein kinase 1
(RIP1)-dependent cell death.
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Results
Drug sensitivity screening of mesothelioma cell lines.
In this study, we aimed at identifying mechanisms accounting
for sensitivity versus resistance towards dual PI3K/mTOR
inhibitors in a large panel of mesothelioma cell lines. In order
to address this question, we performed a cytotoxicity screen
in 19 commercially available mesothelioma cell lines. Cells
were treated with increasing doses of either NVP-BEZ235 or
GDC-0980, and viability and growth inhibition were assayed
by measuring mitochondrial activity at 72 h using an MTT
assay. The IC50 distribution determined for NVP-BEZ235
showed a difference of about 26-fold between the most
sensitive and the most resistant cell lines, whereas
GDC-0980 IC50 distribution was more homogenous and
showed a maximal difference of 8-fold (Figure 1).
In order to determine whether the results obtained were
suitable to select resistant and sensitive cell lines, we tested
whether the percentages of growth and viability for a given
concentration of either GDC-0980 or NVP-BEZ235 were
normally distributed using the Quantile-Quantile Plot (Q-Q Plot)
normality test (Figure 1, Supplementary Figure S1). Both NVP-
BEZ235 and GDC-0980 cell growth inhibition and viability were
normally distributed. The results of viability for NVP-BEZ235
and GDC-0980 were centered at 45.7 and 43.65%, respec-
tively, of untreated control providing maximal sensitivity to
detect both resistant and sensitive lines. Thresholds of sensitive
and resistant cell lines were set using ±1 S.D. from the mean.
The distribution of the cell lines based on the IC50 was
consistent to the one observed in the Q-Q Plot.
The published IC50 of NVP-BEZ235 observed in cell lines
ranges from 10 to 100 nM20,21 and for GDC-0980 varies
between 200 and 500 nM.22 The IC50 of 26% of the MPM cell
lines treated with NVP-BEZ235 waso100 nM and the IC50 of
68% of MPM cell lines cells treated with GDC-0980 was
o500 nM. Based on this observation, the concentration of the
drug used for functional assays for NVP-BEZ235 was set to
200 nM, which includes the IC50 of 58% of the cell lines. For
GDC-0980, 500 nM was chosen.
No differences between sensitive and resistant cell lines
in PI3K/mTORC1/2 signaling. To perform functional assays,
six representative cell lines overlapping in sensitivity and
resistance to both drugs were chosen, including the sensitive
SPC212, ZL34 and Mero-25 and the resistant cell lines Mero-
83, Mero-82 and ONE58. We further examined whether PI3K/
mTORC1/2 activity markers' phosphorylation was differen-
tially inhibited in sensitive versus resistant cell lines and found
no substantial differences at the level of mTORC1 signaling
(Figure 2a). Both inhibitors similarly reduced the phosphor-
ylation of mTORC1 activity markers 4E-BP1 and S6 already
after 4 h of treatment, and this was maintained after 72 h in
a dose-dependent manner. S6 phosphorylation did not
correlate with 4E-BP1 phosphorylation, and this may be
representative on the addiction of cancer cells to aberrant
eIF4F heterotrimer-mediated translation,23 the assembly of
which is inhibited by dephosphorylated 4E-BP1.
Figure 1 Identification of mesothelioma cell lines sensitive versus resistant to PI3K/mTOR inhibition. IC50 of 19 MPM cell lines: ACC-Meso-1, SPC212, MSTO-211H, ZL34,
ZL55, NCI-H2452, ZL5, NCI-H226, SPC111, NCI-H2052, Mero-25, Mero-95, SDM103T2, ACC-Meso-4, Mero-82, ONE58, Mero-14, Mero-84 and Mero-83 and Q-Q Plot
normality test at 250 nM after 72 h treated with (a) NVP-BEZ235 and (b) GDC-0980
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Figure 2 Decrease of PI3K/mTOR signaling is accompanied by G1 arrest, which is more pronounced in sensitive cell lines. (a) Protein lysates of sensitive cell lines SPC212,
ZL34 and Mero-25 and resistant cell lines Mero-83, Mero-82 and ONE58 were analyzed by western blotting against PI3K/mTOR activity markers: phospho-AKT (Thr308),
phospho-AKT (Ser473), AKT, phospho-S6, S6, phospho-4E-BP1, 4E-BP1, and Actin. Each cell line was serum-starved for 16 h and treated as indicated for 4 h with 1000 μg/ml
IGF-1, 0.5 μM NVP-BEZ235, 0.5 μM GDC-0980 or treated for 72 h with increasing concentrations of NVP-BEZ235 or GDC-0980 as indicated. (b) Cell cycle profile of sensitive
cell line SPC212 and resistant line Mero-82 treated with 0.2 μM NVP-BEZ235 or 0.5 μM GDC-0980 for 72 h. Data are presented as means± S.D. from ≥ 3 independent
experiments. Significance was determined by Student's t-test (***Po0.005, **Po0.01 and *Po0.05; NS, not significant)
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GDC-0980 phosphorylation inhibition of mTORC2 substrate
AKT (Ser473) was very efficient at 4 h and maintained after
72 h in most of the lines analyzed, whereas NVP-BEZ235
inhibitory effect decreased after 72 h. Similarly, inhibition of the
PI3K p100 activity marker phosphorylation AKT (Thr308) was
efficient with both drug at 4 h but only the GDC-0980 inhibitory
effect wasmaintained after 72 h for most of the lines analyzed.
Similar results with NVP-BEZ235 were observed by Serra
et al.21 in PI3K/mTORC2 inhibition in breast cancer cells
where only high concentrations of 500 nM achieved efficient
inhibition of PI3K p100. Taken together, although there was no
correlation between markers of PI3K/mTORC1/2 activity and
the cell growth in sensitive and resistant cell lines for both dual
PI3K/mTORC1/2 inhibitors, GDC-0980 was more efficient in
blocking PI3K/mTORC2 compared with NVP-BEZ235.
We further investigated the sensitive line SPC212 and the
resistant cell line Mero-82 based on their ability to grow in 3D
cultures. Cell growth inhibition was confirmed by analyzing the
cell cycle profile for each cell line after 72 h of treatment.
G1 accumulation with 200 nM NVP-BEZ235 and 500 nM
GDC-0980 was significantly more pronounced in the sensitive
lines than the resistant cell lines; however, no cell death was
observed (Figure 2b, Supplementary Figure S2).
PTEN, a negative regulator of the PI3K pathway, was
differentially expressed in all the MPM cell lines tested
(Supplementary Figure S3). The sensitive cell lines Mero-25
and ACC-Meso-1 showed no expression of PTEN, indicating
that overactivation of PI3K pathway predisposes to sensitivity
to the inhibitors.
NF2 loss was shown to sensitize to both PI3K and mTOR
inhibitors.6,11 Only four MPM lines expressed NF2 protein
(NCI-H2452, ACC-Meso-4, MSTO-211H and Mero-25), con-
sistent with previous studies.6,24,25 Of the four lines, three
(NCI-H2452, ACC-Meso-4, MSTO-211H) have documented
wild-type NF2 according to CCLE database and published
data.24,26 Because only few lines express proven wild-type
NF2, it is difficult to draw any conclusion about any correlation
between NF2 status and sensitivity and resistance to dual
PI3K/mTOR inhibitors in our experimental settings.
MPM cell lines have high levels of basal autophagy.
Autophagy is a survival mechanism by which cytosolic
material is sequestered in a double-layered membrane,
autophagosome, delivered to the lysosome for degradation
and recycled to fuel cellular growth in periods of starvation or
distress.27 Cancer can take advantage of this mechanism to
maintain cell viability, leading to tumor dormancy, progression
and therapeutic resistance.28 Consistently with the observa-
tions done by others that NVP-BEZ235 induces autophagy in
glioma cells29–31 and GDC-0980 in pancreatic cancer,32 we
also observed sustained autophagy induction in SPC212 and
Mero-82 cells after 72 h of treatment, evidenced by the
processing of LC3-I to the autophagosome localized LC3-II
form and P62 degradation (Figure 3a). Therefore, we
hypothesized that autophagy could act as resistance
mechanism in our mesothelioma model. We found that
almost all the mesothelioma cells analyzed had high levels
of basal autophagy as indicated by LC3-II form (Figure 3b) as
compared with the non-transformed mesothelial cell line
SDM104. Overnight serum starvation did not considerably
increase the level of basal autophagy in most of the cell lines
analyzed, in contrast to other metabolism adjustments
observed after external growth factor deprivation.33 No
correlations between levels of LC3-II and changes of PI3K/
mTOR signaling regulators such as PTEN, NF2 as well as
mTORC1 activity (documented by S6 phosphorylation)
between resistant and sensitive lines were observed in
serum-deprivation conditions (Supplementary Figure S3).
SPC212 and Mero-82 cells have a high autophagic flux
and autophagy blockade sensitizes them to PI3K/mTOR
inhibitors inducing cell death in a RIP1-dependent
manner. GDC-0980 and NVP-BEZ235 alone or in combina-
tion with other chemotherapeutics or radiotherapy have been
shown to induce intrinsic apoptosis in a variety of solid and
liquid tumors.20,22,29,34–36 Moreover, in cancers, such as renal
cell carcinoma or pancreatic cancer, the combination of
autophagy inhibitor chloroquine (CQ) with single mTOR or
dual PI3K/mTOR inhibitors sensitizes the cells and induces
caspase-dependent and -independent cell death.32,37–39 CQ
is a lysosomotropic drug that raises intralysosomal pH40 and
impairs autophagic protein degradation.
In order to test whether NVP-BEZ235 and GDC-0980
promote survival via autophagy, sensitive and resistant lines
were treated with the inhibitors alone or in combination with
CQ. CQ alone and in combination with GDC-0980 efficiently
blocked autophagy after 24 h of treatment, and this effect was
maintained after 72 h. GDC-0980 alone increased the
autophagic flux in SPC212 and Mero-82 cells at 72 h
(Figure 4a). Strong cytoplasm vacuolization was induced with
CQ treatment alone or in combination with the inhibitors in
both cell lines, supporting the results from the immunoblotting
(Figure 4b). Although a strong morphological impact of CQ
combined with dual PI3K/mTOR inhibitors was observed at
earlier time points, cell death was detected only after 96 h in
the cell lines tested (Figure 4c, Supplementary Figure S4).
We observed a significant ATP drop in both cell lines treated
with CQ alone, and this was less prominent in the resistant line
Mero-82 after 96 h of treatment. The combination showed a
significant additive effect in the reducing ATP levels in SPC212
cells and a minor effect in Mero-82 (Figure 4c), which was
confirmed by colony-formation assay in Mero-82 cells
(Supplementary Figure S5).
In order to confirm the role of autophagy in sensitization to
PI3K/mTOR inhibition, we silenced the Atg5 gene (Figure 5a),
which is important for the autophagosome elongation. Silen-
cing of Atg5 resulted in abolition of P62 accumulation after CQ
treatment (Figure 5b), thus demonstrating efficient blockade of
autophagy. Similar results were observed with a second short
hairpin system (data not shown). Surprisingly, silencing Atg5
gene was associated with significantly impaired cell growth in
SPC212 sensitive line and Mero-82 resistant line (Figure 5c),
indicating the dependency of the MPM on autophagy.
Because of this phenotype, we could not test the effect of
PI3K/mTOR inhibition.
To determine the type of cell death induced by the
combination of CQ and the dual PI3K/mTOR inhibitors, cells
were examined for apoptosis by assessing the Annexin V/PI
viability assay (Figure 6, Supplementary Figure S6), effector
caspase 3 processing and cleavage of the caspase 3
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substrate PARP. We observed cell death induction in both
SPC212 and Mero-82 cells with both inhibitors in the Annexin
V/PI assay; however, significant higher cell death induction
was only achieved when CQ was added. This additive effect
was bigger in the sensitive line SPC212 than in the resistant
line Mero-82. Addition of the broad spectrum pan-caspase
inhibitor Z-VAD-FMK failed to rescue cell death (Figure 6a). No
active caspase-3, PARP cleavage or cytochrome c release
was detected upon combined treatment (Figure 6b,
Supplementary Figure S7), and we also did not observed an
increase of the BH3 only protein BIM (data not shown).
Altogether, these observations support that intrinsic apoptosis
was not involved. We then checked whether the death
observed may occur via RIP1-dependent mechanism.41
SPC212 and Mero-82 cells were treated with CQ and NVP-
BEZ235 or GDC-0980 in the absence and presence of the
specific RIP1 inhibitor Necrostatin-1 (Nec-1).42 Nec-1 alone
was able to significantly block the cell death induced by CQ
and the dual PI3K/mTOR inhibitors in SPC212. In Mero-82
cells, Nec-1 did not block cell death. Furthermore, the dual
PI3K/mTOR inhibitors induced RIP1 degradation (Figure 6c),
which was then rescued by the addition of CQ in both cell lines.
This effect wasmore obvious after 96 h, when the cells started
to die. Interestingly, prosurvival protein X-linked inhibitor of
apoptosis protein (XIAP) was efficiently downregulated as
a result of AKT inhibition only in the sensitive line SPC212 but
not in the resistant line Mero-82.
A number of crosstalk, feedback and feed-forward loops link
the PI3K/AKT/mTOR and Ras/MEK/ERK signaling pathways,
which provide insights into the compensatory responses
observed with targeting either pathway alone.43 We observed
that GDC-0980 induced activation of ERK in resistant Mero-82
cells but not in sensitive SPC212 cells (Supplementary Figure
S8a). ERK activation was also strongly induced by CQ in
resistant Mero-82 cells. To test whether inhibiting the MEK/
ERK pathway would enhance the effect of GDC-0980 and
CQ, we tested U0126, a MEK1/2 inhibitor. U0126 effi-
ciently inhibited ERK induction by CQ and GDC-0980
(Supplementary Figure S8b). However, combination of
U0126, GDC-0980 and CQ did not induce cell death
(Supplementary Figure S8c).
Dual PI3K/mTOR inhibitors in combination with CQ
induce cell death in 3D MPM. Spheroids have been
observed in the pleural fluid of human MPM and linked to
increased malignancy.44 MPM spheroids have been used to
investigate new therapeutic options45 and have shown that
this model better represent biological complexity existing in
patients’ tumor.46,47 Therefore we aimed at verifying in this
model the efficiency of blocking PI3K/mTOR combined with
inhibition of autophagy.
Figure 3 Mesothelioma cells exhibit a high level of autophagy, which is increased upon inhibition of PI3K/mTOR signaling. (a) Anti-P62 and -LC3BI/II and -Actin western blots
of protein lysates of sensitive cell line SPC212 and resistant cell line Mero-82 treated for 72 h with increasing concentrations of NVP-BEZ235 or GDC-0980 as indicated. (b) Anti-
LC3BI/II and -Actin western blots of mesothelial cell line SDM104 and MPM cell lines SPC111, SPC212, NCI-H226, NCI-H2052, NCI-H2452, Mero-14, Mero-25, Mero-82, Mero-
83, Mero-84, Mero-95, ACC-Meso-1, ACC-Meso-4, MSTO-211H and ONE58 left with serum or serum-starved for 16 h. In the lower panel, protein level quantification of LC3BII
normalized against Actin is represented for the cell lines described above with standard culture conditions
PI3K/mTOR signaling and autophagy in mesothelioma
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In this study, we used 300-μm diameter densely packed
spheroids formed in 4 days according to a standardized
protocol.48 In these conditions, about one-third of the cells are
in quiescent state,44 thereby corresponding better to prolifera-
tion status of tumoral cells49 compared with 2D cell culture.
Mero-82 and SPC212 spheroids were treated either with
CQ alone or in combination with NVP-BEZ235 or GDC-0980.
Although treatment with CQ alone did not have an impact on
spheroid growth, there was a significant drop in ATP content of
around 20% for both the cell lines (Figures 7a–c). In addition,
the spheroids were refractive and appeared dark in light
microscopy. Treatment of the spheroids with the PI3K/mTOR
inhibitors alone induced significant cell growth inhibition and
ATP drop in both the cells lines (Figures 7b and c).
Combination of CQ with PI3K/mTOR inhibitors did not have
an additional impact on cell growth per se; however, strong
cytoplasm vacuolization and swelling of the single cells
(Figure 7a) was observed. Moreover, there was a significant
additive effect on ATP reduction for both the cell lines.
Interestingly, in the SPC212 spheroids ATP content was
almost depleted and they appeared disintegrated and
individual cells were recognizable while Mero-82 the spheroid
shape was still intact at the time point of analysis.
Inhibition of autophagy did not sensitize normal SDM
104 cells to PI3K/mTOR inhibition (Supplementary Figures
S9a–c).
In order to test whether ERK pathway is involved in Mero-82
resistance in 3D, we added U0126 (Supplementary Figure
S10). Combination of U0126 and GDC-0980 had a slight
additive effect on viability, and there was no additional
significant effect when CQ was added. Disintegration of the
spheroids was not observed after 6 days of treatment. These
Figure 4 Inhibition of autophagy with CQ sensitizes mesothelioma cell lines to PI3K/mTOR inhibitors. (a) Anti-P62, L-C3BI/II and Actin western blots of protein lysates of
sensitive cell line SPC212 and resistant cell line Mero-82 treated with 20 μM CQ, 0.5 μM GDC-0980 or in combination for 24, 48 and 72 h. (b) Light micrographs of SPC212 and
Mero-82 treated with 0.2 μM NVP-BEZ235, 0.5 μM GDC-0980 alone or in combination with 20 μM CQ for 96 h. Scale bar represents 25 μm. (c) Quantification of the percentage
of ATP content of SPC212 cells and Mero-82 cell treated with 0.2 μM NVP-BEZ235, 0.5 μM GDC-0980 alone or in combination with 20 μM CQ for 96 h. Data are presented as
means± S.D. from ≥ 3 independent experiments. Significance was determined by analysis of variance test (***Po0.005, **Po0.01 and *Po0.05; NS, not significant)
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results indicate that ERK is not the major pathway involved in
cell death resistance.
Discussion
In this study, we demonstrate that shortcut escape into
autophagy is one way to improve therapeutic efficiency of
PI3K/mTOR inhibition in MPM.
Several mechanisms have been described to underlie
resistance to PI3K/mTOR inhibition. For example, breast
cancer cell lines resistant to NVP-BEZ235 have increased
JAK2/STAT5 activation resulting from IL-8 secretion.50 Along
these lines, combined treatment with GDC-0980 together
with a c-Met inhibitor efficiently inhibited mesothelioma tumor
growth in vivo.51 Dual PI3K/mTOR inhibitors were described52
to induce ERK activation by inhibiting mTORC2 in pancreatic
cancer. Combination of PI3K/mTOR and MEK/ERK inhibitors
enhanced the drug response. We observed a similar effect in
the resistant cell line Mero-82; however, the combination of
PI3K/mTOR and MEK/ERK inhibitors, in the presence or
absence of autophagy inhibition, did not result in cell death,
indicating that an additional mechanism might be involved.
Another known resistance mechanisms to PI3K/mTOR inhibi-
tion include cap-independent translation and FOXO-mediated
mechanism.53 NVP-BEZ235 was shown to induce upregula-
tion and/or activation of several prosurvival proteins such as
RTK, cytosolic kinases, antiapoptotic proteins and transcrip-
tion factors mostly by cap-independent translation.54 mRNAs
translated under these conditions have a highly structured 50-
untranslated region, which often harbors an Internal Ribo-
some Entry Site sequence and several upstream AUGs. One
of the protein that is translated in this way under conditions of
reduced global protein synthesis is XIAP.55 XIAP is a key
intrinsic regulator of apoptosis, primarily by virtue of its ability
to bind to and inhibit both initiator and effector caspases.56
Although the cellular levels of XIAP are regulated by several
independent mechanisms, the predominant regulation
appears to be the control of XIAP mRNA translation. Levels
of XIAP were upregulated by GDC-0980 in Mero-82 resistant
but not in SPC212 sensitive cells. Interestingly, XIAP levels
were also upregulated by CQ, but this might be related to other
mechanisms, including autophagy inhibition-driven increase
in the levels of proteasome substrates.57
FOXO-dependent mechanisms may underlie the different
response to the two PI3K/mTOR inhibitors used in this study.
Indeed, mTORC2 was more efficiently inhibited by GDC-0980
compared with NVP-BEZ235, resulting in inhibition of AKT
activation. Atg genes are positively controlled by FoxO3a,58
and the latter is negatively regulated by active AKT. Therefore
GDC-0980 by inducing a better blockage of AKT activation
may result in long-term, FOXO3a-dependent commitment to
autophagy, and indeed we observed decreased phosphoryla-
tion of FOXO3a after GDC-0980 treatment (data not shown).
Our observations are consistent with increased efficiency
observed by inhibition of autophagy together with dual PI3K/
mTOR inhibitors in pancreatic cancer59 and peripheral nerve
sheath tumors.60
The cell death observed in our experimental settings is
most likely necroptosis, which is one of the several forms of
regulated cell death involving RIP1, RIP3 and MLKL.41 The
mechanism activating necroptosis include dropping ATP
levels, which at some point abolish the activity of all ATP-
dependent enzymes (including various transporters that
maintain ionic balance at the plasma membrane) and
Figure 5 Autophagy is necessary for mesothelioma cell growth. SPC212 and Mero-82 cell lines were stable transduced with virus particles carrying Mir30- Sh-Atg5 or Mir30-
Sh-Ctrl. (a) Atg5 gene silencing was confirmed by anti-ATG5 western blotting. (b) Anti-P62, -LC3BI/II and -Actin of SPC212 and Mero-82 Sh-Atg5 and Sh-Ctrl untreated or treated
with 20 μM CQ for 4 h. (c) Fold cell growth of SPC212 and Mero-82 Sh-Atg5 and Sh-Ctrl for 3 days. Data are presented as means±S.D. from three independent experiments.
Significance was determined by Mann–Whitney U-test (*Po0.05)
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a compromised redox balance (which inactivates various
enzymes and causes oxidative molecular damage to orga-
nelles and membranes) as central players in the execution of
regulated cell death.41 We documented a drastic decrease of
ATP levels which supports the theory that cells died due to
necroptosis. The decrease of ATP level wasmore severe in the
sensitive SPC212 cells compared with the resistant Mero-82
cells. Interestingly, cell death induced by combined treatment
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Figure 7 Inhibition of autophagy with CQ combined with inhibition of PI3K/mTOR signaling induces spheroid cell death. (a) Representative light micrographs of SPC212 and
Mero-82 spheroids treated as indicated with 1 μM NVP-BEZ235, 1 μM GDC-0980 and 20 μM CQ for 6 days. (b) Fold increase volume (growth) of spheroids shown in panel
(a). (c) Viability is presented as the percentage of ATP content in SPC212 and Mero-82 spheroids treated as described in panel (a). Data are presented as means±S.D. from≥ 3
independent experiments. Significance was determined by analysis of variance test (***Po0.005 and *Po0.05; NS, not significant)
Figure 6 Inhibition of autophagy with CQ combined with inhibition of PI3K/mTOR signaling induces caspase-independent cell death. (a) SPC212 and Mero-82 cell lines were
treated as indicated with 0.2 μM NVP-BEZ235, 0.5 μM GDC-0980, 20 μM CQ, 20 μM ZVAD-FMK or 50 μM Nec-1 for 96 h. Cell death was assessed by GFP-Annexin V/PI
staining and flow cytometry. Data are presented as means±S.D. from three independent experiments. Significance was determined by analysis of variance test (***Po0.005,
**Po0.01 and *Po0.05; NS, not significant). (b) Anti- PARP, -Caspase 3 and -Actin western blots of SPC212 and Mero-82 treated as indicated with 0.2 μM NVP-BEZ235,
0.5 μM GDC-0980 and 20 μM CQ. SV40 immortalized wt MEFs treated for 15 h with 3 μg/ml Etoposide were used as control for apoptosis. (c) Anti-XIAP (asterisk (*) represents
unspecific band), -RIP1 and -Actin western blots of protein lysates of SPC212 and Mero-82 treated as indicated with 0.2 μM NVP-BEZ235, 0.5 μM GDC-0980 and 20 μM CQ for
72 and 96 h
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was efficiently blocked by RIP1 inhibitor Nec-1 only in the
sensitive cell line SPC212. This indicates that the actual
induction of cell death in the resistant Mero-82 line happens in
a RIP1-independent context, most probably involving only
RIP3 andMLKL.41 The likelihood of this scenario is suggested
by recent data showing that XIAP inhibits TNF- and RIP3-
dependent cell death61 and by our observation that XIAP was
not efficiently downregulated upon combined drug treatment
in Mero-82 compared with SPC212 cells
The results observed were consistent in the 2D and 3D
models. This is important as baseline phosphorylation of
PI3K/AKT/mTOR pathway members have been described to
be reduced in 3D spheroids compared with 2D.47 Because
3D/spheroids represent a closer model to tumor biological
complexity, these results suggest that this combined ther-
apeutic option should be explored in clinical settings.
In addition, we observed that inhibition of autophagy per se
had an effect on mesothelioma cell growth. Autophagy
promotes the survival of cells resistant to apoptosis when
they are deprived of extracellular nutrients or growth factors.
Treatment of such cells dependent on autophagy for survival
with CQ results in ATP-depletion-dependent cell death.62
Inhibition of cancer cells' intrinsic autophagy by silencing Atg5
decreases B16-F10 tumor growth.63 Autophagy has a context-
dependent role in cancer.64 It is upregulated and required for
the survival of tumor cells in hypoxic tumor regions.64
Knocking out essential autophagy genes in genetically
engineered mouse models for cancer have demonstrated
a pro-tumorigenic role for autophagy.65 The mechanisms
behind 'autophagy addiction' observed in MPM cells are
beyond the scope of present study but will be further explored.
In conclusion, we demonstrated the PI3K/mTOR inhibitors
increase autophagy levels in MPM and combination together
with CQ should be further explored as inhibition of autophagy
blocks this resistance mechanism.
Materials and Methods
Reagents. Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham
(DMEM–F12), propidium iodide and Penicillin/Streptomycin 100 × stock solution
were purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Trypsin
solution 0.25% was purchased from GIBCO (Life Technologies Europe, Zug,
Switzerland). Fetal calf serum (FCS, CVFSVF00-01) was purchased from Eurobio
(Ulis (Les), France). Puromycin was purchased from AppliChem (Darmstadt,
Germany). Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD-FMK) was purchased from
BACHEM (Bubendorf, CH, Switzerland). Nec-1 was purchased Enzo LifeSciences
AG (Lausen, Switzerland). NVP-BEZ235 was obtained from Novartis (Basel,
Switzerland) and GDC-0980 was obtained from Genentech (Roche, Basel,
Switzerland). U0126 was purchased from Cell Signaling Technology (Allschwil,
Switzerland). Nivaquine (chloroquine sulfate) was purchased from Sanofi Aventis
(Paris, France). Recombinant His6-GFP-Annexin V was kindly provided by T
Kaufmann (Bern, CH, Switzerland).
Cell culture. The following mesothelioma cell lines have been used: ZL55, ZL5,
ZL34, SDM103T2, SPC111 and SPC212 from our laboratory; NCI-H226, NCI-
H2052, NCI-H2452, MSTO-211H66 were obtained from ATCC (Wesel, Germany);
ACC-Meso-1 and ACC-Meso-424 were obtained from Riken BRC (Ibaraki, Japan);
and Mero-25, Mero-82, Mero-83, Mero-84, Mero-95(ref 67) and ONE58(ref 68) was
obtained from the European Collection of Cell Cultures (Salisbury, UK). The non-
transformed mesothelial cell line SDM104(ref 69) was established in our laboratory.
Cells established in our laboratory were maintained as described by Thurneysen
et al.70 The rest of the cell lines were cultured in DMEM–F12 supplemented with
15% FCS and 1% Penicillin/Streptomycin solution. SV40 immortalized wild-type
MEF cells and Hek 293T cells were cultured in DMEM high glucose medium
supplemented with 10% FCS and 1% Penicillin/Streptomycin. All cells were cultured
at 37 °C in a humidified 5% CO2 atmosphere.
Gel electrophoresis and immunoblotting. Total protein extracts were
prepared by lysing the cells with hot H8 buffer containing 10 mM Tris-Cl pH 7.4,
2 mM EDTA, 2 mM EGTA and 1% SDS and boiled for 5 min. Protein concentration
was determined using a DC Protein Assay (Bio-Rad, Hercules, CA, USA), and
proteins were prepared by adding 6 × reducing Lämmli buffer (600 mM DTT) and
boiling the samples for 5 min. A total of 10 μg protein per extract was separated on
denaturing 4–20% gradient SDS-PAGE gels. Proteins were transferred onto PVDF
transfer membranes (0.45 μm, Perkin Elmer, Schwerzenbach, Switzerland). For
western blotting, membranes were probed with the following primary antibodies:
rabbit anti-AKT (no. 9272), rabbit anti-Phospho-AKT (Thr308) (no. 9275), rabbit anti-
Phospho-AKT (Ser473) (193H12, no. 9275), mouse anti-S6 (54D2, no. 2317), rabbit
anti-Phospho-S6 (Ser235/236) (D57.2.2E, no. 4858), rabbit anti-4E-BP1 (no. 9452),
rabbit-Phospho-4E-BP1 (Thr37/46) (236B4, no. 2855), rabbit anti-p44/42 MAP
Kinase (no. 9102), rabbit anti-Phospho-p44/42 MAP Kinase (Thr202/Tyr 204) (no.
9101), rabbit anti-PTEN (138G6, no. 9559), rabbit anti-LC3B (no. 2775), rabbit anti-
PARP (no. 9542), rabbit anti-caspase-3 (no. 9662) from Cell Signaling Technology;
rabbit anti-NF2 (C18, no. sc-332) from Santa Cruz Biotechnologies (Dallas, TX,
USA); guinea pig anti-p62 (GP62-C) from Progen (Heidelberg, Germany); mouse
anti-RIP (no. 610458) and mouse anti-XIAP (no. 610763) from Transduction
Laboratories (Allschwil, Switzerland); mouse anti-ATG5 (7C6) from Nanotools
(München, Switzerland); rabbit anti-Phospho-NF2 (Ser518) (PAI-14252) from Pierce
(Rockford, IL, USA) and mouse anti-Actin (no. 69100) from MP Biomedicals (Santa
Ana, CA, USA). Membranes were then incubated with the secondary antibody goat
anti-mouse IgG-HRP (A-5420) from Ancell (Bayport, MN, USA), goat anti-guinea pig
IgG-HRP (sc-2438) from Santa Cruz and goat anti-rabbit IgG-HRP (no. 7074) from
Cell Signaling. The signals were detected by enhanced chemiluminescence (ECL
Western Blotting Reagents, GE Healthcare, Glattbrugg, Switzerland) and detected
on photosensitive film (Super RX Fuji x-Ray Film, Fujifilm, Düsseldorf, Germany).
Quantification of cell death by flow cytometry. Floating cells and
attached cells were collected and washed with Annexin V staining buffer (150 mM
NaCl, 4 mM KCl, 2.5 mM CaCl2, 1 mM MgSO4, 15 mM HEPES pH 7.2, 2% FCS
and 10 mM NaN3) and incubated with GFP-Annexin V diluted in staining buffer for
at least 30 min on ice in the dark. Cells were then washed in Annexin V staining
buffer and resuspended in 500 μl staining buffer. Propidium iodide was added to a
final concentration of 2 μg/ml, and cells were examined using on an Attune flow
cytometer (Applied Biosystems, Zug, Switzerland) and analyzed with the Attune
cytometric software v1.2.5 (Applied Biosystems). GFP-Annexin V- and propidium
iodide-positive cells were considered as dead cells.
MTT assay and IC50 calculation. Cells were plated in sextuplicates at a
density of 3000 cells/well in 96-well plates and allowed to adhere overnight
followed by serum starvation for 16 h. The cells were then exposed to 0, 0.001,
0.01, 0.05, 0.1, 0.25, 0.5, 1 and 5 μM of GDC-0980 or NVP-BEZ235 for 1 h in
serum-free condition, and medium containing serum and the inhibitors were
added to the cells and incubated for 72 h. Mitochondrial activity as a readout for
cellular viability was assessed by MTTassay. In all, 10 μl of a 10 mg/ml MTT stock
solution (3-amino-9-ethyl-carbazole, Sigma Aldrich, Buchs, Switzerland) was
added per well containing cells in 100 μl DMEM–F12 without Phenol Red. Plates
were incubated for 90 min at 37 °C and cells lysed with 100 μl MTT lysis buffer
(10% SDS, 45% dimethyl formamide, adjusted to pH 4.7 by 80% acetic acid/1 M
HCl) for 2 h. Absorbance was measured at 570 nm using SpectraMax microplate
reader (Molecular Devices, Sunnyvale, CA, USA). IC50 was calculated using the
GraphPad Prism Software (GraphPad Inc., San Diego, CA, USA). Cell growth
inhibition was assessed using the formula 100 × (t− t0)/(c− t0)= 50, where ‘t’ is
the OD of 72-h exposure time to the test drug, ‘t0’ the OD at time 0 and ‘c’ the
control OD in the absence of drugs.
Cell cycle analysis. For cell cycle analysis, floating cells and attached cells
were collected, washed with D-PBS and fixed with ice cold 70% ethanol on ice for
30 min. Then cells were washed twice with D-PBS and incubated with PI/RNAse
solution (50 μg/ml and 100 μg/ml) at RT for 1 h. Cells were analyzed on an Attune
flow cytometer (Applied Biosystems) and data were processed using the ModFit LT
cell cycle software (Topsham, ME, USA).
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Spheroid formation. To form spheroids, 1000 cells/well for SPC212 and 2000
cells/well for Mero-82 per well were plated on ultra-low attachment 96-well round-
bottomed plates (Sigma-Aldrich). Cells were concentrated by gentle centrifugation
at 300 × g for 5 min and incubated at 37 °C for 4 days in order to reach 250–300 μm
before starting the treatment. For each treatment, triplicates were performed. After
6 days, volume of the spheroid was calculated by measuring the spheroid diameter
on light micrographs. Spheroid growth fold increase was assessed using the formula
(t− t0)/(c− t0); ‘t’= spheroid volume after 6 days of exposure to test drug,
‘t0’= spheroid volume at time 0 and ‘c’= control spheroid volume after 6 days.
Viability was performed by determining the ATP content of the spheroids using
CellTiter-Glo Luminescent Cell Viability Assay (D160963, Promega, Dübendorf,
Switzerland), following the manufacturer's instructions. Luminescence was acquired
using GloMax 96 Microplate Luminometer (Promega).
Lentiviral gene transfer and gene silencing. Two types of short
hairpins targeting Atg5 and their respective controls were used: Atg5 shRNA was
subcloned in pMSCV-Puro-miR30(ref 71) and pLKO.1 ATG5 shRNA (Sigma-Aldrich),
which were kindly provided by Dr. HU Simon (Bern, CH, Switzerland). HEK
293T cells were co-transfected with PMD2.VSV-G (envelope coding sequence):
psPAX2 (packaging elements): shRNA Atg5 or control (total of 5 μg of DNA) at a
ratio of 2:5:3 in 10-cm tissue culture dishes using Lipofectamine 2000 Transfection
Reagent (Life Technologies). Lentiviral particles were harvested from the medium
24 and 48 h later, pooled and passed through a 0.2-μm filter and used fresh for
infection or stored in aliquots at − 80 °C. Target cell lines were transduced in the
presence of 8 μg/ml polybrene. Successfully transduced cells were selected with
0.3 μg/ml puromycin for a minimum of 3 weeks.
Statistical analysis. IC50 was calculated using the GraphPad Prism version
5.0 (GraphPad Inc.). Q-Q Plot was used to identify sensitive and resistant cell lines.
Drug response viability of the cell lines 41 S.D. from the mean were considered
resistant, and the drug response viability of cell lineso1 S.D. from the mean were
considered sensitive. Statistical analyses were performed using StatView version
5.0.1 (SAS Institute, Cary, NC, USA). In order to evaluate statistically significant
differences between normally distributed variables paired, Student’s t-test was used.
To assess significance between variables, which were not normally distributed,
Mann–Whitney U-test was used. To determine significant additive effects between
combination treatments and inhibition of cell death with the inhibitors, ANOVA test
was performed. Differences were considered significant when Po0.05.
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